MedChem
This article was originally published in The Gray Sheet
Executive Summary
President and Chief Operating Officer Edward Covell is appointed president of the company's Gesco International division, assuming responsibility for the intravenous access business. Covell's old post is not expected to be filled and he will continue to report to Chief Executive Officer Jonathan Donaldson. MedChem Senior VP-Sales & Marketing Bradford Gay is appointed president of MedChem's surgical division, overseeing the hemostasis business. The Woburn, Massachusetts firm says the restructuring will "sharpen its focus on its two strategic business units: the hemostasis business (the Avitene family of products) and the intravenous access business"
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.